Table 2. Adverse events and sub-types by tumor primary.

	Total (N = 3137)	CNS NAE†,‡ (n = 23)	PNS NAE† (n = 31)	Other irAE (n = 1122)	None (n = 1961)
Tumor primary
Lung	1406 (44.82%)	3 (13.04%)	11 (35.48%)	440 (39.22%)	952 (48.52%)
Melanoma	446 (14.22%)	9 (39.13%)	8 (25.81%)	256 (22.82%)	173 (8.82%)
Renal	196 (6.25%)	6 (26.09%)	5 (16.13%)	90 (8.02%)	95 (4.84%)
Other	1089 (34.71%)	5 (21.74%)	7 (22.58%)	336 (29.95%)	742 (37.79%)

^†Significant (p < 0.05) compared with “None”.

^‡Significant (p < 0.05) compared with “Other”.

All tests performed using Fisher’s exact test.

‘Other Tumor primary’ includes: breast, cervical, cutaneous squamous, endometrial, esophageal, gastric, hepatocellular, Hodgkin lymphoma, Merkel cell, urothelial.

CNS: Central nervous system; irAE: Immune-related adverse event; NAE: Neurological adverse event; PNS: Peripheral nervous system.